The purpose of this research is to evaluate how well people tolerate the treatment, assess its safety, measure the immune system response, and determine how effective it is at reducing episodes of genital herpes. The study will compare the new treatment to placebo to understand if it can help reduce the frequency of herpes outbreaks in people with recurring infections.

During the study, participants will receive multiple doses of either the study treatment or placebo. They will need to keep track of any symptoms in an electronic diary and attend follow-up visits. The researchers will monitor participants for any side effects at the injection site (such as redness or pain) and general body reactions (such as fever or tiredness). Blood samples will be collected to check how the immune system responds to the treatment.

The purpose of the study is to assess how well pritelivir works in treating these specific HSV infections compared to other treatments chosen by the investigator. Participants will receive treatment for a maximum of 28 days, and the study will monitor the healing of lesions, the recurrence of the virus, and any side effects experienced by the participants. The trial will also look at how quickly the lesions heal and how long it takes for any pain associated with the lesions to stop.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather data on the effectiveness of the treatments. The trial aims to provide valuable information on the best ways to manage acyclovir-resistant HSV infections in people with compromised immune systems, potentially leading to improved treatment options in the future.

Participants in the study will be randomly assigned to receive either the 2LHERP treatment or a placebo, which looks like the treatment but does not contain the active ingredients. This helps researchers understand the true effect of the treatment. The study is conducted in a double-blind manner, meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo, ensuring unbiased results. The main goal is to evaluate if 2LHERP can decrease the frequency of herpes outbreaks over a 12-month period.

Throughout the study, participants will be monitored for any changes in the number of herpes episodes they experience. Researchers will also observe other factors such as the time it takes for the first recurrence of herpes after starting the treatment, the average duration of each episode, the level of pain during outbreaks, and the overall quality of life. The study will also track any side effects or adverse events that may occur. This research is expected to provide valuable insights into the potential benefits of 2LHERP for managing recurrent orofacial herpes.

The purpose of the study is to understand how acyclovir affects the health outcomes of these patients, specifically looking at survival rates over a 30-day period. Participants in the study will receive either acyclovir or a placebo, and their progress will be monitored over time. The study will also track other factors such as the number of days patients can breathe without the help of a machine, the length of their stay in the hospital, and their overall quality of life during and after the treatment.

Throughout the study, researchers will collect data to see if acyclovir helps reduce the presence of HSV-1 in the lungs and improves the patients’ recovery. The study aims to provide valuable insights into the potential benefits of using acyclovir for patients with pneumonia and HSV-1, ultimately helping to improve treatment strategies for these serious conditions.